Pancreatic Cancer: Progress in Systemic Therapy

Pancreatic Cancer: Progress in Systemic Therapy.

BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the Western world. Due to lack of specific symptoms and no accessible precursor lesions, primary diagnosis is commonly delayed, resulting in the identification of only 15-20% of patients with potentially curable disease. The major limiting factor is an already locally advanced or metastatic disease...

Medical therapy for advanced pancreatic cancer: work in progress.

New directions in systemic therapy of pancreatic cancer.

BACKGROUND The aggressiveness of pancreatic adenocarcinoma makes it a deadly disease, with its incidence rate and fatality rate almost equal. Surgery represents the only means to provide cure to patients with pancreatic cancer, though the 5-year survival is less than 10%. METHODS We review the data on surgical and systemic therapies and provide more details on a newer biologically based medic...

reatment for Pancreatic Cancer : Current Therapy and ontinued Progress

s T n the last decade, continued efforts in pancreas cancer esearch have led to the development of new, more ffective therapies. Additionally, progress in understandng the molecular processes underlying the developent and progression of this disease provides hope for he development of more effective treatment strategies. ecent clinical trials have provided reason for hope that ovel chemotherapy...

Adjuvant systemic therapy for early breast cancer: progress and controversies.

The diagnosis and management of breast cancer have changed considerably over the past 4 decades. The introduction of adjuvant endocrine therapy (ovarian ablation) and adjuvant chemotherapy in the 1960s was a paradigm-changing event, based on improved understanding of the natural history of human breast cancer and the increased realization that micrometastases were in existence in most patients ...